Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

37P - Prognostic Significance of Immune Checkpoint Molecule Expression in Resectable Gastric Adenocarcinoma

Date

06 Oct 2021

Session

e-Posters

Presenters

Vlad Croitoru

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

V.M. Croitoru1, A. Filippi2, I.M. Cazacu3, S. Kitahara4, A. Matsui4, G. Lauwers4, A. Sorop2, L.G. Necula5, L. Matei5, C. Pechianu2, A.E. Croitoru3, V. Herlea2, A. Saftoiu6, M. Chivu-Economescu5, S. Dima2, D.G. Duda4, I. Popescu2

Author affiliations

  • 1 Fundeni Clinical Institute, Bucharest/RO
  • 2 Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 77085 - Bucharest/RO
  • 3 Fundeni Clinical Institute, 22328 - Bucharest/RO
  • 4 Massachusetts General Hospital, Boston/US
  • 5 Stefan St. Nicolau Institute of Virology, Bucharest/RO
  • 6 University of Medicine and Pharmacy Craiova, Craiova/RO
More

Abstract 37P

Background

Survival rates of gastric cancer remain poor and, hence, there is a great need to identify novel treatment strategies and relevant predictive and prognostic biomarkers. Immunotherapies targeting the PD-1/PD-L1 checkpoints have shown promising results, but simultaneous inhibition of other immune checkpoint molecules may further improve clinical outcome. The expression and prognostic significance of other immune checkpoint molecules have not been extensively explored, especially among resectable gastric cancer patients. Herein, we prospectively examined the expression of several immune checkpoints and their correlation with survival in patients with resectable gastric cancer.

Methods

39 patients who underwent curative surgery for gastric adenocarcinoma at Fundeni Clinical Institute were included in this study. The expression patterns of several immune checkpoints with either co-stimulatory, such as CD28, inducible T-cell CO-Stimulator (ICOS), CD27, glucocorticoid-induced tumor necrosis factor receptor (GITR), or co-inhibitory activity, including PD-1, CTLA4, BTLA, lymphocyte-activation gene 3 (LAG3), TIM3 and IDO, were examined on immune cells using Luminex xMAP technology with ProcartaPlex Human Immuno-Oncology Checkpoint Marker panel 14-plex from tumoral and peritumoral resected specimens.

Results

Increased LAG-3 and GITR expression in primary tumors were independent factors for prolonged overall survival (p=0.02 and p=0.008, respectively). Conversely, ICOS was associated with shorter overall survival (p=0.04). Moreover, ICOS expression in primary tumors was significantly associated with PD-1 expression while GITR expression was positively correlated with TIM-3. No statistically significant association was found between the other immune checkpoint molecules and survival.

Conclusions

Our results indicate that increased expression levels of LAG-3, GITS and ICOS are independent prognostic factors for overall survival in patients with curatively resected gastric cancer. These immune checkpoint molecules should be further evaluated as novel predictive and/or therapeutic targets for gastric cancer patients.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.